经济观察报 记者 张铃 2026年1月23日，深夜11点，李文辉和隋建华走进一家西北餐厅，两碗炒面，是这对科学家夫妻的晚餐，也是他们的庆功宴。 李文辉是病毒学家，隋建华是抗体工程专家，他们同为北京生命科学研究所（下称"北生所"）研究员、华辉安健联合创始人。吃这顿特别晚餐那天，是他们 最重要作品诞生的日子。经过十余年共同研究，全球病毒性肝炎领域第一款单抗药物立贝韦塔单抗注射液（下称"立贝韦塔"）获批上市。 下午5点半，国家药监局披露立贝韦塔获批的消息，这之后，夫妻俩做的第一件事就是挨个回复国内外传来的祝贺，直到深夜。李文辉是兰州人，他原本想 带隋建华吃碗牛肉拉面，但赶到餐厅时，最后一锅汤已经被收起来了。第二天，他们没有像往常周末那样早早出门工作，而是继续在家给一路上支持过立贝 韦塔的同道们发感谢信，那是他们罕见的"偷懒"时刻。 "感谢了那么多人，其实，我最想感谢的是这个时代。"隋建华说。 在他们创立华辉安健的2015年，中国政府启动药审改革，此后10年，中国创新药开启了新时代，逐渐与世界接轨。在产业政策扶持及各方资本支持下，华辉 安健从一家只有几名员工、一个临床前分子的初创企业，成长为一家有上百名员工、多个推进 ...

Group 1: Industry Insights - The growth of online pharmaceutical sales is driven by the penetration of original research drugs and the outflow of prescriptions, with foreign companies increasing their presence in outpatient settings for innovative drugs [1] - Major pharmaceutical e-commerce and internet healthcare platforms are enhancing their product and service offerings around original research drugs, leading to a rapid increase in market share for medical e-commerce [1] - The long-term potential for online pharmacies is significant due to policy-driven factors such as online insurance and prescription outflow, highlighting the cost-effectiveness and convenience of online pharmacies [1] Group 2: Company Performance - Alibaba Health's self-operated revenue is accelerating, with self-operated business accounting for nearly 90% of total revenue, driven by the trend of original research drugs [2] - The number of self-operated SKUs increased by 99% year-on-year to 1.61 million, with revenue growing by 19% year-on-year to 14.38 billion yuan as of FY26H1 [2] - Alibaba Health is the largest online B2C healthcare retail platform in terms of annual GMV and has revised the upper limit of its advertising service framework agreement, which will significantly contribute to profitability [1][2] Group 3: Future Opportunities - The integration of AI in health management presents new opportunities for Alibaba Health, with the potential to enhance sales through the "Qianwen Super Agent" and related applications [2] - The company is exploring serious medical applications and has launched the medical AI assistant "Hydrogen Ion" App, which may lead to commercialization through partnerships with pharmaceutical companies [2] Group 4: Financial Projections - Revenue forecasts for Alibaba Health are projected at 34.594 billion yuan and 38.235 billion yuan for the fiscal years 26 and 27, respectively, with adjusted net profits expected to be 2.499 billion yuan and 3.026 billion yuan [2] - The pharmaceutical e-commerce business is assigned a 3X PS for FY26, while the healthcare and digital services business is assigned a 6X PS, leading to a target value of 7.39 HKD per share and a "Buy" rating [2]

Core Viewpoint - BeiGene's subcutaneous formulation of Tislelizumab has received implied approval from the National Medical Products Administration for clinical trial supplementation, aimed at treating malignant tumors, marking a significant advancement in drug formulation that is expected to enhance patient compliance and market potential [1] Stock Performance - As of February 13, 2026, BeiGene's A-shares (688235) were priced at 279.62 CNY, with a 5-day cumulative increase of 2.61%; Hong Kong shares (06160) were at 208.60 HKD, up 1.66% over the same period; while U.S. shares (ONC.OQ) were at 346.07 USD, down 2.22% [2] - On February 13, 2026, A-share net outflow of main funds was 8.49 million CNY, with a trading volume of 316 million CNY, indicating short-term profit-taking pressure influenced by market sentiment and company events [2] Financial Report Analysis - BeiGene plans to release its financial results for Q4 and the full year of 2025 on February 26, 2026; preliminary data shows a revenue of 27.595 billion CNY for the first nine months of 2025, a year-on-year increase of 44.21%, and a net profit attributable to shareholders of 1.139 billion CNY, up 130.88% year-on-year [3] - The high growth in performance is primarily driven by the sales expansion of core products like Tislelizumab, with investors advised to focus on annual profitability and globalization progress [3] Institutional Perspectives - In the past 90 days, 9 institutions have rated BeiGene, with 8 giving a buy rating and 1 an outperform rating, setting a target average price of 320.0 CNY [4] - Analysts indicate that the company's fundamentals are robust, with strong globalization progress and profitability, although financial risks and market competition should be monitored [4]

Core Insights - The company has achieved significant global growth over the past year, marking a critical turning point towards profitability with its core self-developed BTK inhibitor, Baiyueze, establishing a leading position globally [1] - The company has launched its second self-developed product in the hematology field, the BCL2 inhibitor Baiyueda (Sotuximab), which is now commercially available [1] - The company has expanded its global footprint, with products available in over 75 markets and more than 2 million patients receiving treatment worldwide [1] Global Expansion and Market Impact - In Thailand, the approval process for Baizean took only 7 months, significantly reducing the time for patients to access innovative treatments [2] - In India, two self-developed products have benefited over 1,500 patients with positive clinical feedback [2] - The company is supporting the first immunotherapy clinical trial in sub-Saharan Africa through the provision of PD-1 inhibitors [2] - The Guangzhou production base not only serves domestic patients but also extends to markets in Indonesia, India, and South Korea, continuously expanding the company's global reach [2] Commitment to Innovation and Accessibility - The company aims to enhance drug accessibility in more countries and regions while continuing to expand its pipeline with a focus on scientific innovation [3] - The commitment to making innovative treatments available to more patients globally is seen as a long-term investment and a driving force for the company [3] Milestone Year - The year 2025 is highlighted as a milestone for the company, marking its 15th anniversary and a clearer, more determined new starting point in its globalization journey [4] Collaboration and Knowledge Sharing - The company emphasizes the importance of collaboration with various industry stakeholders to gather diverse experiences and insights, aiming to illuminate hope for more patients through scientific exploration [5]

Core Viewpoint - The article discusses the current funding logic in the market, highlighting the significant movements of public funds in the technology sector, particularly in the semiconductor and biopharmaceutical industries, as they adjust their portfolios based on performance and valuation metrics [3][8]. Group 1: Public Fund Movements - Public funds have shown a notable shift in their holdings, particularly in the STAR Market, with the STAR 50 Index rising by 12.1% this year [3][4]. - The total market capitalization of STAR Market companies reached 10.4 trillion yuan, with the technology sector dominating, accounting for 62.1% of the total market cap [5][6]. - The semiconductor industry remains the core focus for fund allocation, with 12 companies in the sector having a market capitalization exceeding 10 billion yuan [9][11]. Group 2: Semiconductor Sector Insights - The market's pricing anchor for the semiconductor sector has shifted from "valuation expansion" to "performance realization," emphasizing the importance of actual earnings [13][14]. - Key drivers for future growth in the semiconductor sector include strong order backlogs, profit growth through acquisitions and expansions, and sustained price increases in advanced processes [13][14]. - Public funds have significantly increased their holdings in semiconductor materials, chip design, and equipment, with companies like ShenGong Co. seeing an 11% increase in fund holdings [15][21]. Group 3: Biopharmaceutical Sector Insights - The biopharmaceutical sector is a critical area for public funds, with major holdings in companies like BeiGene and United Imaging Healthcare, although the sector has faced a reduction in holdings for several key companies [24][26]. - The article notes that innovative drug companies are currently under pressure, with significant reductions in holdings observed in companies like BaiLi TianHeng and RongChang Biopharma [26][28]. - Despite the challenges, companies with strong earnings potential and innovative drug pipelines are still attracting interest from public funds, indicating a selective investment approach [35][40].

Group 1 - In 2025, Chinese biopharmaceutical companies achieved a record high in outbound licensing deals, surpassing $137.7 billion, nearly a tenfold increase from 2021, with 186 transactions [1] - Major global pharmaceutical companies, including Novartis, AstraZeneca, and GSK, signed significant agreements with Chinese firms last year [1] - Tom Barsha from Bank of America Securities predicts that the total value of these licensing deals could double again in the next 18 to 24 months, as global companies focus on finding next-generation innovative drug pipelines in China [1] Group 2 - AstraZeneca announced a collaboration with China’s CSPC Pharmaceutical Group, potentially worth up to $18.5 billion, to develop a next-generation GLP-1 class weight loss therapy [2] - The average deal size for outbound licensing by Chinese pharmaceutical companies has reached $1.3 billion this year, a 76% increase from 2025 and six times the average level of 2021 [2] - Macquarie Capital analysts noted that many multinational companies view China as a crucial part of their global R&D infrastructure, especially as they face patent cliffs and seek to reduce costs [2]

Core Insights - Many multinational companies are increasingly viewing China as a crucial part of their global R&D infrastructure, especially as they face patent cliffs and seek to cut costs [1][4] - The value of licensing agreements for new drugs from Chinese biopharmaceutical companies is expected to reach a historic high of over $100 billion by 2025, with a total of $137.7 billion in licensing deals signed in 2025, nearly a tenfold increase from 2021 [1][4] Group 1 - Global pharmaceutical giants, including Novartis, AstraZeneca, and GSK, signed multiple significant agreements with Chinese companies last year [3] - Tom Barsha, head of Asia-Pacific M&A at Bank of America Securities, predicts that the total value of these licensing deals could double again in the next 18 to 24 months, as global companies focus on finding next-generation innovative drug pipelines in China [3] - There have been nearly 40 licensing transactions involving Chinese biopharmaceutical companies this year, with average deal sizes significantly higher than last year [3] Group 2 - The average deal size for licensing agreements from Chinese pharmaceutical companies this year has reached $1.3 billion, a 76% increase from 2025 levels and approximately six times the average from 2021 [4] - The average upfront payment this year is $77.7 million, doubling from $38.8 million in 2025 and tripling from the average in 2021 [4] - Macquarie Capital's Asia healthcare research department predicts that a class of drugs considered foundational for cancer treatment will continue to attract global pharmaceutical interest [4] Group 3 - Many multinational companies are recognizing China's strength in chemical fields, allowing them to obtain promising molecular licenses at lower costs compared to internal R&D [4] - Vision Lifesciences' report highlights that China is a world leader in specific molecular types, with Chinese companies accounting for nearly 90% of global licensing deals for antibody-drug conjugates (ADCs) [4]

Core Insights - Recent developments for BeiGene include the approval of a supplemental application for the subcutaneous formulation of Tislelizumab for malignant tumor treatment, which is expected to enhance patient compliance and market potential [1] - The company plans to release its financial results for Q4 and the full year of 2025 on February 26, 2026, which will be followed by a board meeting and a conference call for investors [1] Stock Performance - BeiGene's stock has shown volatility recently, with A-shares closing at 279.62 CNY, down 1.09% on February 13, 2026, but up 2.61% over the past five days; Hong Kong shares closed at 208.60 HKD, down 0.48%, with a 1.66% increase over five days; and US shares at 350.12 USD, up 1.07% on the same day but down 1.07% over five days [2] - On February 12, 2026, A-share main funds experienced a net outflow of 18.68 million CNY, with a trading volume of 311 million CNY, indicating some profit-taking pressure amid market sentiment [2] Financial Analysis - Preliminary data shows that for the first nine months of 2025, BeiGene reported revenue of 27.595 billion CNY, a year-on-year increase of 44.21%, and a net profit attributable to shareholders of 1.139 billion CNY, up 130.88% [3] - The significant growth in performance is primarily driven by the sales expansion of core products like Tislelizumab, and investors should pay attention to the company's profitability and globalization progress in the upcoming financial report [3]

Group 1 - The year 2025 marks a milestone for the company, celebrating its 15th anniversary and entering a clearer phase in its globalization process [2] - The company achieved significant global growth in the past year, reaching a critical profitability turning point, with its core self-developed BTK inhibitor, Baiyueze, establishing a leading position globally [2] - The company launched its second self-developed product in the hematology field, the BCL2 inhibitor Baiyueda (Sotukral), which is now commercially available [2] Group 2 - In Thailand, the approval process for Baizean took only 7 months, significantly reducing the time for patients to access innovative treatments [3] - In India, the company's two self-developed products have benefited over 1,500 patients, receiving positive clinical feedback [3] - The company is expanding its global footprint by supporting local commercialization efforts in Indonesia and providing PD-1 inhibitors for clinical trials in sub-Saharan Africa [3] Group 3 - The company's goals for 2026 remain clear: to continue pipeline expansion centered on science and to enhance drug accessibility for patients in more countries [4] - The commitment to making innovations accessible to more patients is seen as a long-term investment and a driving force for the company [4] - The company emphasizes the importance of collaboration with industry partners to gather diverse experiences and wisdom from different regions to improve patient outcomes globally [4]

Group 1 - BeOne Medicines AG (NASDAQ:ONC) is recognized as a high growth international stock, with a Buy rating and a price target of $414 from Bernstein and $394 from Barclays [1][2][4] - The company received the first-in-world approval for its drug Sonrotoclax in China, aimed at treating relapsed/refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) [2][4] - The MCL study showed a 52.4% overall response rate (ORR) and the CLL/SLL study demonstrated a 77% ORR, indicating strong efficacy of Sonrotoclax [4] Group 2 - Management emphasizes that the approval in China is part of a global rollout strategy for BeOne Medicines AG [4] - Bernstein's Rebecca Liang believes the company's pipeline is undervalued and highlights Sonrotoclax as having potential best-in-class status [4] - BeOne Medicines AG is a global oncology company focused on innovative cancer treatments for hematology and solid tumors [4]